BACKGROUND Hepatitis B virus(HBV)infection is a leading cause of global hepatocellular carcinoma(HCC).Conventional biomarkers such as alpha-fetoprotein(AFP)demonstrate suboptimal sensitivity and specificity.Emerging e...BACKGROUND Hepatitis B virus(HBV)infection is a leading cause of global hepatocellular carcinoma(HCC).Conventional biomarkers such as alpha-fetoprotein(AFP)demonstrate suboptimal sensitivity and specificity.Emerging evidence suggests that serum extra spindle pole bodies like 1(ESPL1)protein and p53 antibody may improve diagnostic accuracy.AIM To assess and compare the diagnostic performance of serum ESPL1 protein and p53 antibody in HBV-related HCC(HBV-HCC).METHODS This case-control study from the First Affiliated Hospital of Guangxi Medical University enrolled 30 patients with chronic hepatitis B(CHB),30 with HBV-related liver cirrhosis(HBV-LC),55 with HBV-HCC,and 30 healthy controls.Serum ESPL1 protein and p53 antibody levels were quantified via ELISA.Diagnostic performance was evaluated using receiver operating characteristic(ROC)curve analysis,including sensitivity,specificity,and correlation with AFP.RESULTS Serum ESPL1 protein levels progressively increased across disease stages(CHB:89.9 ng/L;HBV-LC:188.83 ng/L;HBV-HCC:317.63 ng/L),with a significantly higher area under the ROC curve(AUC=0.917)than either p53 antibody(AUC=0.725)or AFP(AUC=0.678).p53 antibody levels were significantly elevated only in the HBVHCC group.ESPL1 demonstrated superior sensitivity and concordance with histopathological findings.A significant correlation between ESPL1 and p53 antibody levels was observed exclusively in the HBV-HCC group(r=0.320,P=0.017),suggesting potential interplay in malignant transformation.CONCLUSION Serum ESPL1 protein,a promising biomarker for early HBV-HCC detection,outperforms p53 antibody in diagnostic reliability.Higher ESPL1 levels correlate with increased HCC risk in chronic HBV patients.展开更多
The cytokine repertoire of ADP/ATP carrier-specific humoral immune responses and the cytokine-dependent anti-ADP/ATP carrier antibody IgG subclasses were examined in a cohort of ADP/ATP carrier-immunized BALB/c mice t...The cytokine repertoire of ADP/ATP carrier-specific humoral immune responses and the cytokine-dependent anti-ADP/ATP carrier antibody IgG subclasses were examined in a cohort of ADP/ATP carrier-immunized BALB/c mice treated with anti-CD4 monoclonal antibody. Eighteen male BALB/c mice （6–8 weeks old） were randomized into 3 groups： dilated cardiomyopathy （DCM） group, DCM-tolerance （Tol） group and control group. The mice in DCM group were immunized with the peptides derived from human ADP/ATP carrier protein for 6 months and mice in the control group were sham-immunized, while the mice in DCM-Tol group were immunized with ADP/ATP carrier protein and anti-CD4 McAb simultaneously. Serum autoantibody against ADP/ATP carrier and IgG subclasses were measured by ELISA, intracellular cytokines IFN-γ and IL-4 of Th cells were moni- tored with flow cytometry, and splenic T cell cytokines IFN-γ, IL-2, IL-4 and IL-6 were detected by using real-time fluorescent quantitative PCR. The results showed that the autoantibody against ADP/ATP carrier was found in all mice in DCM group, and the antibody level, serum IgG1 and IgG2a subclasses, cytokines in T cells and Th cells were all elevated in DCM group, as compared with those in control group （P〈0.01）. On the other hand, in DCM-Tol group, the autoantibody level and contents of all the cytokines were significantly different from those in DCM group （P〈0.01）, and were close to those in control group. And the levels of IgG1, IgG2a, IgG2b and IgG3 were influenced, to varying degrees, by anti-CD4 McAb as compared with those in DCM group. All these four types of IgG subclasses were substantially decreased in DCM-Tol group as compared with DCM group. It is concluded that the treatment with anti-CD4 McAb could prevent the activation of T cells, reverse the abnormal secretion of cytokines and the imbalance between Th1/Th2 cell subsets and abnormal production of autoantibody against ADP/ATP carrier, and eventually avoid myocardial injuries.展开更多
Using the purified VP1 protein of Asia 1 type foot-and-mouth disease virus as the antigen, the purified monoclonal antibody was labeled by the sodium periodate method and the monoclonal antibody competitive ELISA was ...Using the purified VP1 protein of Asia 1 type foot-and-mouth disease virus as the antigen, the purified monoclonal antibody was labeled by the sodium periodate method and the monoclonal antibody competitive ELISA was established in this study. Ten positive porcine foot-and-mouth disease serums and more than two hundreds negative serum were tested, and the results were the same as the background of samples. The sensitivity test and replicate test indicated that this method was stable and sensitive, which was suitable for monitoring Asia 1 type porcine foot-and-mouth disease virus antibody.展开更多
目的探讨新四极体-1(NET-1)在结肠癌中的表达、临床意义及预后分析。方法收集50例结肠癌组织和50例癌旁正常组织,应用逆转录聚合酶链反应法(RT-PCR)和Western blot检测两组中NET-1 mRNA和蛋白质的表达情况,并应用免疫组化法(SP)检测NET-...目的探讨新四极体-1(NET-1)在结肠癌中的表达、临床意义及预后分析。方法收集50例结肠癌组织和50例癌旁正常组织,应用逆转录聚合酶链反应法(RT-PCR)和Western blot检测两组中NET-1 mRNA和蛋白质的表达情况,并应用免疫组化法(SP)检测NET-1在两组中的表达,分析NET-1在结肠肿瘤发生、发展中的作用,并随访、分析NET-1的表达与结肠癌患者生存的相关性。结果 RT-PCR结果显示NET-1 mRNA在结肠癌和癌旁正常组织中的表达水平分别为(0.95±0.07)和(0.26±0.04),差异有统计学意义( P =0.005);Western blot结果显示:NET-1蛋白在结肠癌和癌旁正常组织中的表达水平分别为(0.83±0.09)(0.22±0.03),差异有统计学意义( P =0.003);SP法结果表明NET-1蛋白在结肠癌和癌旁正常组织中的阳性表达分别为64.00%(32/50)和36.00%(18/50),差异有统计学意义( P <0.001);NET-1与肿瘤的TNM分期、脉管浸润、淋巴结转移及肝转移等病理参数密切相关;NET-1阳性组的中位生存时间为299 d(95% CI :230.07~303.93),阴性组的中位生存时间为387 d(95% CI :279.16~335.82),差异有统计学意义( P =0.031)。NET-1表达水平与结肠癌患者预后明显相关( RR =2.092, P =0.002)。结论 NET-1的异常表达在结肠癌病变的发生、发展中具有重要作用,且与患者的生存期亦明显相关,是结肠癌潜在的生物学指标。展开更多
基金Supported by National Natural Science Foundation of China,No.81960115,No.82160123 and No.82260124Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor(Guangxi Medical University),Ministry of Education,No.GKEZZ202107+1 种基金Guangxi Key Laboratory of Early Prevention and Treatment for Regional High Frequency Tumor,No.GKE-ZZ202218Guangxi Science and Technology Program,No.AD25069077.
文摘BACKGROUND Hepatitis B virus(HBV)infection is a leading cause of global hepatocellular carcinoma(HCC).Conventional biomarkers such as alpha-fetoprotein(AFP)demonstrate suboptimal sensitivity and specificity.Emerging evidence suggests that serum extra spindle pole bodies like 1(ESPL1)protein and p53 antibody may improve diagnostic accuracy.AIM To assess and compare the diagnostic performance of serum ESPL1 protein and p53 antibody in HBV-related HCC(HBV-HCC).METHODS This case-control study from the First Affiliated Hospital of Guangxi Medical University enrolled 30 patients with chronic hepatitis B(CHB),30 with HBV-related liver cirrhosis(HBV-LC),55 with HBV-HCC,and 30 healthy controls.Serum ESPL1 protein and p53 antibody levels were quantified via ELISA.Diagnostic performance was evaluated using receiver operating characteristic(ROC)curve analysis,including sensitivity,specificity,and correlation with AFP.RESULTS Serum ESPL1 protein levels progressively increased across disease stages(CHB:89.9 ng/L;HBV-LC:188.83 ng/L;HBV-HCC:317.63 ng/L),with a significantly higher area under the ROC curve(AUC=0.917)than either p53 antibody(AUC=0.725)or AFP(AUC=0.678).p53 antibody levels were significantly elevated only in the HBVHCC group.ESPL1 demonstrated superior sensitivity and concordance with histopathological findings.A significant correlation between ESPL1 and p53 antibody levels was observed exclusively in the HBV-HCC group(r=0.320,P=0.017),suggesting potential interplay in malignant transformation.CONCLUSION Serum ESPL1 protein,a promising biomarker for early HBV-HCC detection,outperforms p53 antibody in diagnostic reliability.Higher ESPL1 levels correlate with increased HCC risk in chronic HBV patients.
基金the National Natural Science Foundation of China (No. 30000070)
文摘The cytokine repertoire of ADP/ATP carrier-specific humoral immune responses and the cytokine-dependent anti-ADP/ATP carrier antibody IgG subclasses were examined in a cohort of ADP/ATP carrier-immunized BALB/c mice treated with anti-CD4 monoclonal antibody. Eighteen male BALB/c mice （6–8 weeks old） were randomized into 3 groups： dilated cardiomyopathy （DCM） group, DCM-tolerance （Tol） group and control group. The mice in DCM group were immunized with the peptides derived from human ADP/ATP carrier protein for 6 months and mice in the control group were sham-immunized, while the mice in DCM-Tol group were immunized with ADP/ATP carrier protein and anti-CD4 McAb simultaneously. Serum autoantibody against ADP/ATP carrier and IgG subclasses were measured by ELISA, intracellular cytokines IFN-γ and IL-4 of Th cells were moni- tored with flow cytometry, and splenic T cell cytokines IFN-γ, IL-2, IL-4 and IL-6 were detected by using real-time fluorescent quantitative PCR. The results showed that the autoantibody against ADP/ATP carrier was found in all mice in DCM group, and the antibody level, serum IgG1 and IgG2a subclasses, cytokines in T cells and Th cells were all elevated in DCM group, as compared with those in control group （P〈0.01）. On the other hand, in DCM-Tol group, the autoantibody level and contents of all the cytokines were significantly different from those in DCM group （P〈0.01）, and were close to those in control group. And the levels of IgG1, IgG2a, IgG2b and IgG3 were influenced, to varying degrees, by anti-CD4 McAb as compared with those in DCM group. All these four types of IgG subclasses were substantially decreased in DCM-Tol group as compared with DCM group. It is concluded that the treatment with anti-CD4 McAb could prevent the activation of T cells, reverse the abnormal secretion of cytokines and the imbalance between Th1/Th2 cell subsets and abnormal production of autoantibody against ADP/ATP carrier, and eventually avoid myocardial injuries.
基金Supported by National High-tech R&D Program (863) Subsidized Project(2006AA10A204)Special Fund for Basic Scientific Research-related Subsidy of State-level and Public-welfare Scientific Research Institutes~~
文摘Using the purified VP1 protein of Asia 1 type foot-and-mouth disease virus as the antigen, the purified monoclonal antibody was labeled by the sodium periodate method and the monoclonal antibody competitive ELISA was established in this study. Ten positive porcine foot-and-mouth disease serums and more than two hundreds negative serum were tested, and the results were the same as the background of samples. The sensitivity test and replicate test indicated that this method was stable and sensitive, which was suitable for monitoring Asia 1 type porcine foot-and-mouth disease virus antibody.
文摘目的探讨新四极体-1(NET-1)在结肠癌中的表达、临床意义及预后分析。方法收集50例结肠癌组织和50例癌旁正常组织,应用逆转录聚合酶链反应法(RT-PCR)和Western blot检测两组中NET-1 mRNA和蛋白质的表达情况,并应用免疫组化法(SP)检测NET-1在两组中的表达,分析NET-1在结肠肿瘤发生、发展中的作用,并随访、分析NET-1的表达与结肠癌患者生存的相关性。结果 RT-PCR结果显示NET-1 mRNA在结肠癌和癌旁正常组织中的表达水平分别为(0.95±0.07)和(0.26±0.04),差异有统计学意义( P =0.005);Western blot结果显示:NET-1蛋白在结肠癌和癌旁正常组织中的表达水平分别为(0.83±0.09)(0.22±0.03),差异有统计学意义( P =0.003);SP法结果表明NET-1蛋白在结肠癌和癌旁正常组织中的阳性表达分别为64.00%(32/50)和36.00%(18/50),差异有统计学意义( P <0.001);NET-1与肿瘤的TNM分期、脉管浸润、淋巴结转移及肝转移等病理参数密切相关;NET-1阳性组的中位生存时间为299 d(95% CI :230.07~303.93),阴性组的中位生存时间为387 d(95% CI :279.16~335.82),差异有统计学意义( P =0.031)。NET-1表达水平与结肠癌患者预后明显相关( RR =2.092, P =0.002)。结论 NET-1的异常表达在结肠癌病变的发生、发展中具有重要作用,且与患者的生存期亦明显相关,是结肠癌潜在的生物学指标。
